Meglitinide Market Size & Share Analysis - Growth Trends & Forecasts (2026 - 2031)

Global Meglitinide Market Trends and Insights

Rising Type 2 Diabetes Burden

The increasing prevalence of type 2 diabetes continues to drive demand in the Meglitinides market, particularly in countries where affordability and treatment access are key priorities. The IDF estimated that 589 million adults aged 20 to 79 years were living with diabetes in 2025, representing 11.11% of the global adult population. This figure is projected to reach 853 million by 2050. Middle-income countries recorded the highest age-standardized diabetes prevalence at 11.46%, positioning China, India, and Brazil as key demand centers. The IDF also reported diabetes prevalence of 12.26% in urban areas and 9.23% in rural areas. This gap highlights the importance of peri-urban primary care centers in diabetes management and treatment delivery.^[1]

Repaglinide remains competitive due to its affordability, oral administration, and established use among general practitioners. Low-cost generic products remain relevant where patient out-of-pocket spending or payer budget limitations restrict access to newer medicines. China’s 2025 National Reimbursement Drug List includes repaglinide, nateglinide, and mitiglinide calcium as Category B drugs. This reimbursement coverage supports access across public hospitals and community health centers. The Meglitinides market benefits when national reimbursement systems continue to support established oral treatment options, particularly in cost-sensitive healthcare systems.

Need for Postprandial Glucose Control

Meglitinides support patients who require glucose control aligned with meal timing. Their short-acting, glucose-dependent mechanism helps manage postprandial glucose excursions that may persist with longer-acting therapies. The American Diabetes Association recommends reassessing meglitinide doses when initiating a new glucose-lowering medicine to manage treatment burden and hypoglycemia risk.

The drug class remains relevant for patients whose meal patterns or clinical requirements favor short-acting therapy. Meal-responsive treatment is particularly applicable in Japan, China, South Korea, and Germany, where physician familiarity and patient needs support continued use. In Japan, 41.6% of physicians surveyed in September 2025 identified mitiglinide as their most frequently prescribed rapid-acting insulin secretagogue. Mitiglinide ranked ahead of repaglinide at 35.5% and nateglinide at 22.9%. Its selective Kir6.2/SUR1 channel activity and lower within-class hypoglycemia incidence support its use in older patients and those with cardiovascular concerns.^[2] These clinical attributes enable the Meglitinides market to retain a focused role as treatment algorithms evolve.

Continued Use of Oral Antidiabetic Therapies

Oral therapies remain important for many patients initiating treatment for type 2 diabetes. A 2025 study of 964,914 U.S. adults initiating glucose-lowering therapy found that GLP-1 receptor agonist prescribing increased 13.66-fold in incidence rate between 2019 and May 2024. However, GLP-1 receptor agonists accounted for only 18% of new treatment initiators by mid-2024.^[3]

Metformin, generic sulfonylureas, and meglitinides therefore continue to serve a substantial patient base in primary care. Generic repaglinide is priced below newer branded medicines, supporting its position in cost-conscious treatment plans. The supplied evidence placed monthly semaglutide costs at USD 950, compared with USD 15 to USD 40 for generic repaglinide. Oral administration also supports adoption where injectable therapies are not preferred or accessible. This cost difference is significant in countries with high out-of-pocket medicine spending. Public procurement, essential-medicine policies, and primary care prescribing consequently support the Meglitinides market across Africa, Southeast Asia, and South America.

Role in Combination Therapy

Meglitinides can be used with metformin, thiazolidinediones, DPP-4 inhibitors, and basal insulin, supporting their role in combination regimens. Fixed-dose combinations of repaglinide and metformin combine meal-related insulin secretion with reduced hepatic glucose output in a single tablet. This format can reduce the pill burden for patients managing multiple medicines. These combinations are particularly relevant in South Asia, Southeast Asia, South America, the Middle East, and Africa, where simpler oral regimens can improve adherence. Fixed-dose combination products are forecast to expand at a CAGR of 4.85% through 2031, making them the fastest-growing product type in the Meglitinides market.

Their growth reflects the requirements of primary care settings managing large patient populations. Safety oversight remains important for combination medicines. India is set to ban 35 irrational fixed-dose combinations in 2025, creating a stricter compliance environment for manufacturers. The supplied evidence did not identify repaglinide combinations among the banned products.

Hypoglycemia Risk

Hypoglycemia remains a key clinical constraint on the broader adoption of meglitinides. The American Diabetes Association advises clinicians to reassess meglitinide dosages when adding another glucose-lowering medication. This guidance is particularly relevant in markets where clinicians closely follow updated treatment standards. Older patients require careful monitoring, as hypoglycemic events can lead to falls, hospitalization, and other complications.

The need for meal-linked dosing also increases the treatment burden for patients with irregular eating patterns. However, this limitation does not result in the complete withdrawal of the drug class. Physicians may prefer mitiglinide because of its relatively lower within-class incidence of hypoglycemia. Concerns regarding weight gain and frequent meal-dependent dosing reduce the convenience of meglitinides in North America, Europe, and Australia. Therefore, the meglitinides market relies on appropriate patient selection and careful dose management rather than broad first-line adoption. The class continues to serve specific patient segments requiring short-acting glucose control.

Competition From Newer Antidiabetic Therapies

GLP-1 receptor agonists and SGLT2 inhibitors are reshaping treatment decisions in high-income markets. A 2025 U.S. analysis showed that GLP-1 receptor agonist use among new type 2 diabetes treatment initiators reached 18% by May 2024. During the same period, SGLT2 inhibitor use increased to 7%. These therapies can displace older oral agents when insurance coverage and patient affordability support adoption.

The shift is most prominent among commercially insured and premium patient segments. Novo Nordisk is expected to launch a Wegovy pill in the United States in January 2026, expanding oral GLP-1 treatment options. The company is also expected to enter a partnership with Vivtex Corp. in February 2026, valued at up to USD 2.1 billion, to develop oral delivery technologies for obesity and diabetes medications. These initiatives are likely to increase competitive pressure on established oral antidiabetic drug classes. However, the high cost of newer therapies continues to limit substitution in price-sensitive settings. The meglitinides market retains a role for patients with kidney disease tolerance requirements, irregular meal patterns, or complex treatment regimens requiring an affordable, short-acting option.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Molecule: Repaglinide Leads Through Generic Availability, While Mitiglinide Gains Ground

Repaglinide held 53.45% of the meglitinides market by molecule in 2025. Broad generic availability, national formulary inclusion, and an established clinical track record supported its leading position. Its availability as monotherapy and in fixed-dose combinations further strengthened adoption. The product supports meal-related insulin secretion with relatively rapid clearance.

Nateglinide held a smaller market share but addressed demand from patients who benefit from a short half-life and lower interaction potential. As a phenylalanine derivative, it provides a rapid insulin response. Mitiglinide is projected to record the highest growth among molecules, at a CAGR of 3.45% through 2031. A September 2025 physician survey in Japan ranked mitiglinide first among rapid-acting insulin secretagogues, while China retained mitiglinide calcium on its 2025 reimbursement list.

By Product Status: Generics Lead, While Originator Products Retain Selected Demand

Generic formulations held 65.78% of the meglitinides market by product status in 2025. Patent expirations and established bioequivalence pathways supported generic adoption across key molecules. Active pharmaceutical ingredient supply from India and China reinforced price competition. In the United States, Macleods Pharmaceuticals, Aurobindo Pharma, Chartwell RX LLC, and Rising Pharma Holdings supply repaglinide products, while CMS pricing data showed a price of USD 0.09 per tablet in July 2026.

Originator products are forecast to grow at a CAGR of 4.67% through 2031, driven by sustained demand in selected countries. Glufast retains brand recognition in Japan, while hospital tenders and physician familiarity support demand in Germany and Brazil. NovoNorm remains the originator reference product for repaglinide in the European Union. European pharmacovigilance and manufacturing requirements also maintain quality standards for originator and generic medicines.

By Product Type: Single-Ingredient Products Lead, and Fixed-Dose Combinations Expand

Single-ingredient products accounted for 72.45% of the meglitinides market size in 2025. Their leading position reflects the historical use of meglitinides as standalone therapies. Physicians can adjust dosing based on patients' meal patterns and glucose targets. These products remain widely used in Japan, North America, and Europe, supported by American Diabetes Association guidance on dose reassessment with other glucose-lowering medicines.

Fixed-dose combinations are forecast to grow at a CAGR of 4.85% through 2031. Repaglinide and metformin tablets are available in 0.5 mg/250 mg, 1 mg/500 mg, and 2 mg/500 mg strengths. These combinations integrate prandial insulin secretion with reduced hepatic glucose output in a single dose. Demand is concentrated in emerging markets, where primary care providers favor simplified oral regimens that can improve adherence.

By Distribution Channel: Retail Pharmacies Lead, While Online Pharmacies Grow Faster

Retail and community pharmacies accounted for 48.95% of the market in 2025. Their leading role reflects the chronic and predominantly outpatient nature of diabetes care. Community pharmacies provide essential dispensing services in China, India, Japan, and Brazil. Their proximity to primary care clinics and reimbursement coverage supports repeat dispensing for long-term therapy.

Online pharmacies are forecast to expand at a CAGR of 5.23% through 2031. Telemedicine and repeat online prescriptions are increasing direct-to-patient dispensing among stable diabetes patients. Digital channels provide convenience for patients requiring recurring refills. Hospital pharmacies will retain a role in specialist care but may lose share as outpatient management expands, while mail-order pharmacies served 360,000 repaglinide claims for 92,000 Medicare Part D beneficiaries in the United States in 2024.

Geography Analysis

North America is expected to account for 39.88% of the global meglitinides market in 2025. The United States remains the region’s primary revenue contributor, supported by generic product availability and a broad community pharmacy patient base. Six approved repaglinide manufacturers are expected to serve the U.S. market. By mid-2026, repaglinide prices are projected at USD 0.09–0.10 per tablet, reinforcing its position as a low-cost oral treatment option.

The region faces mounting pressure from updated treatment guidelines and the increased adoption of GLP-1 receptor agonists and SGLT2 inhibitors. The ADA has narrowed the role of meglitinides and emphasized the reassessment of hypoglycemia risk. Canada and Mexico provide smaller but stable volumes through public drug benefit programs. Europe remains stable, supported by formulary utilization in Germany, France, and the United Kingdom, which issued a Tier 2 repaglinide supply notification in August 2025 for 500 mcg, 1 mg, and 2 mg tablets.

Asia-Pacific is forecast to be the fastest-growing region, registering a CAGR of 5.51% through 2031. Japan supports demand through established mitiglinide use, while China provides public reimbursement for all three primary molecules. India and Southeast Asia drive uptake of repaglinide-metformin combinations. The IDF Western Pacific region included 215 million adults with diabetes in 2024, while the Middle East and North Africa is projected to record 95% growth in diabetes cases by 2050. Brazil and Argentina support demand through public procurement of low-cost oral treatments.